Takeda Pharmaceutical Company Limited

Yuji Ishichi

Naoyuki Kanzaki

Yuji Ishihara

Takayuki Doi

Hiroshi Nagabukuro

Motoki Ikeuchi

Tsuneo Oda

Shogo Marui

Yasushi Hattori

Hideo Suzuki

Tatsuki Koike

Shuji Hinuma

Masaki Seto

Yasutaka Hoashi

Masami Yamada

Norihito Tokunaga

Masato Yoshida

Yuichi Kajita

Yuhei Miyanohana

Takahiro Matsumoto

Yoshihide Tomata

Tohru Miyazaki

Taku Kamei

Ikuo Fujimori

Koichiro Fukuda

Yoshihiro Banno

Tatsuhiko Fujimoto

Nobuki Sakauchi

Tetsuya Tsukamoto

Tomokazu Kusumoto

Fumio Itoh

Tomoya Yukawa

Kentaro Rikimaru

Taisuke Tawaraishi

Yuji Kawamata

Hiromichi Sugimoto

Yoshihisa Nakada

Hyun Bin Kang

Takatoshi Yogo

Hye Sun Jeon

Hiroyuki Nagamiya

Yusuke Ohba

Cheolhwan Yoon

Chul Yun Rhim

Mariko Hirohashi

Kwang Ok Kim

Gil Nam Lee

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Heterocyclic compound and application thereof

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compound

Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof.

Heterocyclic compounds

Agents for improving potency of the urinary bladder which comprise an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholinesterase and an action to improve the excretory potency of the urinary bladder. As an example, crystals of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed.

Agents and crystals for improving excretory potency of urinary bladder

It is intended to provide a TGR5 receptor agonist containing a fused ring compound represented by the following general formula, its salt or a prodrug thereof: (1) wherein ring A represents an optionally substituted aromatic ring; and the ring B' represents a 5- to 8-membered ring having one or more substituents; which is useful in treating various diseases. 

Receptor agonists

Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an &#x3b1;1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.

Preventives/remedies for urinary disturbance

Growing community of inventors

Sakai, Japan

Yuji Ishichi